VeriSIM Life October Newsletter
VeriSIM Life
Introducing BIOiSIM, an AI-driven drug development engine designed to de-risk and inform R&D decision-making.
It was a historic month for artificial intelligence with two AI pioneers, John Hopfield and Geoffrey Hinton, winning the Nobel Prize in physics - a milestone that cements AI as an undeniable force in science that cannot be overlooked. Meanwhile, VeriSIM Life has had an exciting month of its own, with highlights that include being named a finalist as Most Innovative Company of the Year in the 21st annual Stevie® Awards for Women in Business, and announcing a second partnership agreement with Mayo Clinic. Reach out to a member of our team to learn how our BIOiSIM platform can help you get life-saving drugs to patients faster.
Meet With Us at AAPS PharmSci 360
If you’re attending AAPS PharmSci 360, be sure not to miss our Head of Biosimulations, Dr. Divesh Bhatt present “AI-Driven Innovations for Advanced Pharmaceutical Formulation Development.” During this session, he will explore how the BIOiSIM platform minimizes translational risk, enables research teams to make early and data-driven decisions, and ultimately enhances clinical success rates. In addition to that, our team will be available to schedule individual meetings to discuss how our AI engine can support your drug development objectives.
VeriSIM Life Named a Winner in Stevie Awards “Most Innovative Company of the Year” Category
VeriSIM Life was excited to announce that we were named a finalist in the Most Innovative Company of the Year category in the 21st annual Stevie® Awards for Women in Business. The Stevie Awards honor women executives, entrepreneurs, employees and the companies they run, worldwide. More than 1,500 entries from organizations and individuals in 36 nations and territories were submitted this year for consideration in more than 100 categories, so this was quite the recognition! The finalists’ Gold, Silver, and Bronze Stevie Award placements will be revealed in November.
Recommended by LinkedIn
VeriSIM Life Announces Second Collaboration with Mayo Clinic
This month, VeriSIM Life announced its second collaboration agreement with Mayo Clinic, aimed at accelerating the development of new therapies for liver and metabolic diseases. The collaboration will leverage Mayo Clinic's extensive clinical and research expertise along with VeriSIM Life's pioneering AI-powered platform to address critical unmet medical needs. "This partnership is a significant step forward in advancing the next generation of therapies, driven by a shared commitment to innovation, patient care, and addressing the unmet needs of those suffering from challenging conditions," said Dr. Jo Varshney, Founder and CEO of VeriSIM Life.
Blog: How AI Enables the Use of Real World Evidence in Drug Development
Real world evidence (RWE), which encompasses a wealth of data from electronic health records, patient-reported outcomes, and other sources, offers invaluable insights into drug safety and effectiveness in real-world settings. In this blog post, we discuss how AI is becoming a transformative force in harnessing RWE to improve drug development and for addressing challenges that come with RWE such as data quality, patient privacy, and bias.
What We’re Reading - AI in Drug Design: From Hype to Real-World Results
“If you have a hybrid car, you use gas and electricity,” Dr. Varshney explains in this Genetic Engineering & Biotech News (GEN) article. “Likewise, in our case, we combine mathematical models and machine learning into our hybrid AI mechanistic models.” Check out what she and other experts in the field are saying about AI's potential to solve challenging problems in drug development.